Biofeedback training for glaucoma patients
Part of Eyes & vision clinical trials.
This study tests if biofeedback training—a technique that helps you learn to use your remaining vision better—can improve vision in people with glaucoma. It focuses on those with vision loss near the center of their sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 95 years old.
- You have glaucoma and your eye pressure is well-controlled.
- You have a small blind spot (scotoma) close to the center of your vision.
- You can follow instructions for the biofeedback training.
- You have not had prior low vision rehabilitation treatment.
- You do not have other eye diseases or serious health conditions unrelated to glaucoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a home-based exercise program can lower eye pressure and protect the optic nerve in people with glaucoma. It is designed for patients whose eye pressure is already controlled by medication.
This trial tests if active video games and exercise can help people with glaucoma improve their balance and daily function. It's for people who have stable vision loss and can still walk independently.
This study looks at different ways to measure how glaucoma affects your vision over time by comparing visual field results. It may help researchers find better models to track progression so treatment decisions can be made more accurately.
This trial tests whether combining a short vision learning program with non-invasive electrical stimulation to the brain can improve vision in people with open-angle or normal-tension glaucoma. It may help by training the visual system while stimulating brain pathways to support vision.
This study tests a non-invasive brain stimulation treatment to see if it can improve peripheral (side) vision in people with open-angle or normal-tension glaucoma. It targets people whose central vision is still relatively preserved but whose side vision has a measurable “gap” on vision testing.
This study measures how blood flows in the retina and how well the eye regulates that flow. It compares people with early or very early glaucoma to people without glaucoma to see what differences may predict progression.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.